MENU
MAY 02, 2017 8:00 AM PDT

Counteracting tumor evasion of antibody immunity, free webinar and Q&A session

Sponsored by: Abcam
Speaker
  • Professor of Molecular Medicine, Robert A. Welch Distinguished University Chair in Chemistry; Director, Texas Therapeutics Institute University of Texas Health Science Center at Houston
    BIOGRAPHY

Abstract

DATE: May 2, 2017
TIME: 8:00am PT, 11:00am ET, 4:00pm GMT, 5:00pm CET

The natural immune responses that patients develop to their own tumors, as well as therapeutic regimens employing the latest anti-cancer monoclonal antibodies, would reasonably be expected to suppress tumor growth. Yet, a perplexing resistance to both is widespread. The ineffectiveness of the immune system to prevail in these situations suggests that cancers possess tactics to evade antibodies that could otherwise eradicate them. 

With a clinical context in mind, we observed that tumor-associated protein-degrading enzymes can diminish, and in some cases negate, cell killing functions by inducing a single clip in a small part of the antibody structure. The structural modification is so subtle that it had not been previously recognized and would not have been anticipated to so profoundly impair the antibody. To be able to visualize and establish if such cleavage occurred in cancer, we had to develop innovative antibodies for that exact purpose. 

The new antibodies readily enabled the visualization of antibody damage when incubated with cancer cells in the laboratory or within tumor tissues obtained from animals or human patients - more importantly - the same antibody tools possessed the additional and remarkable property of restoring the lost functions to the damaged antibodies. The “rescue” of lost function suggested that this could be exploited as a therapy in cases where tumors cause antibody damage in order to evade our immune system. This novel therapeutic strategy represents a potentially new direction in cancer immunotherapy.

This webinar will review:

  • A minor proteolytic cleavage at IgG hinge greatly impairs the effector functions of anticancer antibodies
  • Proteolytic hinge cleavage of IgGs as a mechanism of tumor evasion of antibody-based immunity
  • The potential of “rescue” of lost IgG Fc function as a novel therapeutic strategy for cancer

Learning Objectives:

  • Review mechanisms of tumor cells used to evade interaction from anti-cancer antibodies 
  • Learn how antibody technology can be used to develop antibodies capable of visualizing subtle, specific modifications
  • Learn about a potential novel cancer therapeutic method of ‘’restoring’’ antibodies damaged by tumor-associated protein-degrading enzymes

Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
OCT 12, 2021 9:00 AM PDT
C.E. CREDITS
OCT 12, 2021 9:00 AM PDT
Date: October 12, 2021 Time: 9:00am (PDT), 12:00pm (EDT) SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization o...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
MAY 02, 2017 8:00 AM PDT

Counteracting tumor evasion of antibody immunity, free webinar and Q&A session

Sponsored by: Abcam

Specialty

Cancer Research

Immunology

Biotechnology

Molecular Biology

Cell Biology

Cancer Therapeutics

Biomarkers

Cancer Diagnostics

Clinical Diagnostics

Molecular Diagnostics

Clinical Research

Oncology

Infectious Disease

Genetics

Antibodies

Geography

North America64%

Asia14%

Europe11%

South America5%

Africa3%

Oceania1%

Registration Source

Website Visitors100%

Job Title

Executive16%

Scientist13%

Research Scientist13%

Student11%

Medical Laboratory Technician8%

Medical Doctor/Specialist8%

Facility/Department Manager7%

Lab Management6%

Educator/Faculty5%

Clinical Laboratory Scientist3%

Post Doc3%

Biologist2%

QC/QA1%

Marketing/Sales1%

Chemist1%

Organization

Biotech Company12%

Academic Institution10%

Hospital8%

Clinical Laboratory5%

Pharmaceutical Company4%

Life Science Company3%

Research Institute2%

Consultant2%

Medical School2%

Ambulatory Care2%

Medical Center2%

Contract Research Organization (Cro)1%

Non-Profit Organization1%

Industrial Company1%

Other1%


Show Resources
Loading Comments...
Show Resources